Literature DB >> 26071561

Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.

Alessandra Zingoni1, Francesca Cecere2, Elisabetta Vulpis2, Cinzia Fionda2, Rosa Molfetta2, Alessandra Soriani2, Maria Teresa Petrucci3, Maria Rosaria Ricciardi3, Daniel Fuerst4, Maria Giulia Amendola2, Joannis Mytilineos4, Cristina Cerboni2, Rossella Paolini2, Marco Cippitelli2, Angela Santoni5.   

Abstract

Genotoxic stress can promote antitumor NK cell responses by upregulating the surface expression of activating ligands on cancer cells. Moreover, a number of studies suggested a role for soluble NK group 2D ligands in the impairment of NK cell tumor recognition and killing. We investigated whether genotoxic stress could promote the release of NK group 2D ligands (MHC class I-related chain [MIC]A and MICB), as well as the molecular mechanisms underlying this event in human multiple myeloma (MM) cells. Our results show that genotoxic agents used in the therapy of MM (i.e., doxorubicin and melphalan) selectively affect the shedding of MIC molecules that are sensitive to proteolytic cleavage, whereas the release of the short MICA*008 allele, which is frequent in the white population, is not perturbed. In addition, we found that a disintegrin and metalloproteinase 10 expression is upregulated upon chemotherapeutic treatment both in patient-derived CD138(+)/CD38(+) plasma cells and in several MM cell lines, and we demonstrate a crucial role for this sheddase in the proteolytic cleavage of MIC by means of silencing and pharmacological inhibition. Interestingly, the drug-induced upregulation of a disintegrin and metalloproteinase 10 on MM cells is associated with a senescent phenotype and requires generation of reactive oxygen species. Moreover, the combined use of chemotherapeutic drugs and metalloproteinase inhibitors enhances NK cell-mediated recognition of MM cells, preserving MIC molecules on the cell surface and suggesting that targeting of metalloproteinases in conjunction with chemotherapy could be exploited for NK cell-based immunotherapeutic approaches, thus contributing to avoid the escape of malignant cells from stress-elicited immune responses.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26071561     DOI: 10.4049/jimmunol.1402643

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.

Authors:  Elisabetta Vulpis; Francesca Cecere; Rosa Molfetta; Alessandra Soriani; Cinzia Fionda; Giovanna Peruzzi; Giulio Caracciolo; Sara Palchetti; Laura Masuelli; Lucilla Simonelli; Ugo D'Oro; Maria Pia Abruzzese; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Rossella Paolini; Marco Cippitelli; Angela Santoni; Alessandra Zingoni
Journal:  Oncoimmunology       Date:  2017-01-13       Impact factor: 8.110

2.  p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.

Authors:  Alessandra Soriani; Cristiana Borrelli; Biancamaria Ricci; Rosa Molfetta; Alessandra Zingoni; Cinzia Fionda; Silvia Carnevale; Maria Pia Abruzzese; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Giuseppe La Regina; Erica Di Cesare; Patrizia Lavia; Romano Silvestri; Rossella Paolini; Marco Cippitelli; Angela Santoni
Journal:  Oncoimmunology       Date:  2016-12-02       Impact factor: 8.110

3.  Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells.

Authors:  Fabrizio Antonangeli; Alessandra Soriani; Biancamaria Ricci; Andrea Ponzetta; Giorgia Benigni; Stefania Morrone; Giovanni Bernardini; Angela Santoni
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

4.  microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells.

Authors:  Haitao Xie; Qiugui Zhang; Hui Zhou; Jun Zhou; Ji Zhang; Yan Jiang; Jinghong Wang; Xianglin Meng; Leping Zeng; Xiaoxin Jiang
Journal:  Cytotechnology       Date:  2017-05-26       Impact factor: 2.058

Review 5.  A guide to senolytic intervention in neurodegenerative disease.

Authors:  Suckwon Lee; Ellen Y Wang; Alexandra B Steinberg; Chaska C Walton; Shankar J Chinta; Julie K Andersen
Journal:  Mech Ageing Dev       Date:  2021-10-08       Impact factor: 5.432

Review 6.  Cellular senescence and Alzheimer disease: the egg and the chicken scenario.

Authors:  Sara Saez-Atienzar; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2020-06-29       Impact factor: 34.870

7.  Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.

Authors:  Maria Pia Abruzzese; Maria Teresa Bilotta; Cinzia Fionda; Alessandra Zingoni; Alessandra Soriani; Elisabetta Vulpis; Cristiana Borrelli; Beatrice Zitti; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Rosa Molfetta; Rossella Paolini; Angela Santoni; Marco Cippitelli
Journal:  J Hematol Oncol       Date:  2016-12-01       Impact factor: 17.388

Review 8.  How Mucosal Epithelia Deal with Stress: Role of NKG2D/NKG2D Ligands during Inflammation.

Authors:  Fabrizio Antonangeli; Alessandra Soriani; Cristina Cerboni; Giuseppe Sciumè; Angela Santoni
Journal:  Front Immunol       Date:  2017-11-20       Impact factor: 7.561

9.  Downregulation of NKG2DLs by TGF-β in human lung cancer cells.

Authors:  Young Shin Lee; Hojung Choi; Hae-Ryung Cho; Woo-Chang Son; You-Soo Park; Chi-Dug Kang; Jaeho Bae
Journal:  BMC Immunol       Date:  2021-07-12       Impact factor: 3.615

Review 10.  Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis.

Authors:  Rosa Molfetta; Linda Quatrini; Angela Santoni; Rossella Paolini
Journal:  Int J Mol Sci       Date:  2017-08-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.